A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France

Abstract

A597Hospitals (ATIH). Costs and outcomes were discounted at 4% through 30 years and 2% thereafter. Robustness of results was assessed using sensitivity analyses. The assessed outcomes were the incremental cost per quality-adjusted life-year (QALY) gained and total life-years gained (LYG). Results: This study will inform public decision making about reimbursement of mild-to-moderate OSAHS treatments. CPAP was associated with higher costs and QALYs compared with dental devices, lifestyle advice and no treatment. Several sensitivity analyses were undertaken and it was found that the most sensitive parameters were related to sleepiness and cardiovascular inputs. Further investigation (clinical trial/observational study) of treatment effects on these parameters is needed. ConClusions: This analysis is the first to assess the cost-effectiveness of treatments in mild-to-moderate OSAHS patients in France.